- Published at
- by investing.com
positive
positive
Xoma Royalty's chief investment officer buys $13,974 in stock By Investing.com
Xoma Royalty's chief investment officer buys $13,974 in stock
News for XOMA Corporation (0M26.L)
- Published at
- by gurufocus.com
positivepositiveXOMA (XOMA) Stock Surges Amid Positive Market Movement
XOMA Corporation (XOMA) experienced a significant stock movement, with its price rising by 5.45% to $32.70 per share. The trading volume reached 32,220 shares,- Published at
- by seekingalpha.com
mixedmixedXOMA Corporation: A Hold Rating With Steady Income From Preferred Shares (NASDAQ:XOMA)
XOMA Corporation operates as a biotechnology royalty aggregator, acquiring economic rights to milestones and royalties from approved or clinical-stage drugs.- Published at
- by globenewswire.com
mixedmixedXOMA Declares Quarterly Preferred Stock Dividends
July 2024 Dividends...- Published at
- by globenewswire.com
mixedmixedJasper Therapeutics Announces Appointment of Svetlana Lucas Ph.D., to its Board of Directors
REDWOOD CITY, Calif., June 19, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused...- Published at
- by seekingalpha.com
positivepositiveImmunityBio, LadRx end licensing deal for cancer drug (OTCQB:LADX)
LadRx (LADX) and ImmunityBio (IBRX) have ended their licensing deal for aldoxorubicin, allowing LadRx to regain control of the potential cancer drug. Read more here.- Published at
- by marketscreener.com
positivepositiveLadRx and ImmunityBio Mutually Agree to Terminate Aldoxorubicin License
Aldoxorubicin Returns to LadRx ...- Published at
- by globenewswire.com
mixedmixedXOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities
Earned $9 million milestone upon U.S. Food and Drug Administration’s approval of Day One’s OJEMDA™ (tovorafenib); XOMA is entitled to receive a mid-single...- Published at
- by marketscreener.com
positivepositiveXOMA : 2024 Letter to Shareholders
DEAR XOMA STOCKHOLDERS, We made good progress over the course of 2023 towards advancing the company's differentiated royalty business model. [...] This is an abstract of the document. To keep...- Published at
- by globenewswire.com
positivepositiveXOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)
XOMA is entitled to a mid-single digit royalty on global OJEMDA™ sales First and only FDA-approved type II RAF inhibitor for patients with relapsed or...- Published at
- by marketscreener.com
positivepositiveXOMA : Acquisition/Asset Disposal - Form 8-K -April 03, 2024 at 09:30 am EDT
Item 2.01 Completion of Acquisition or Disposition of Assets. ...- Published at
- by marketscreener.com
mixedmixedINVESTIGATION ALERT: Halper Sadeh LLC Investigates LABP, FUSN, KNTE -March 25, 2024 at 03:30 pm EDT
NEW YORK, March 25, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or...- Published at
- by globenewswire.com
positivepositiveBRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Agiliti, Inc. (NYSE – AGTI), Landos Biopharma, Inc. (Nasdaq – LABP), Fusion Pharmaceuticals Inc. (Nasdaq - FUSN
BALA CYNWYD, Pa., March 25, 2024 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to...- Published at
- by globenewswire.com
positivepositiveBRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Fusion Pharmaceuticals Inc. (Nasdaq - FUSN), Whole Earth Brands, Inc. (Nasdaq – FREE), Kinnate Biopharma Inc. (
BALA CYNWYD, Pa., March 19, 2024 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to...- Published at
- by marketscreener.com
mixedmixedSHAREHOLDER UPDATE: Halper Sadeh LLC Investigates FREE, HRT, NGM, KNTE -March 18, 2024 at 10:54 pm EDT
NEW YORK, March 18, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or...- Published at
- by globenewswire.com
mixedmixed- Published at
- by globenewswire.com
mixedmixed- Published at
- by globenewswire.com
mixedmixedXOMA Reports Fourth Quarter and Full Year 2023 Financial
Raised up to $140 million of non-dilutive non-recourse capital through a royalty-backed loan related to VABYSMO® from funds managed by Blue Owl Capital ...- Published at
- by globenewswire.com
mixedmixedC4 Therapeutics Strengthens Board of Directors with Owen Hughes Appointment
Owen Hughes, Accomplished Life Sciences Executive with Deep Experience Across Investing, Operations and Governance, Appointed as Independent Member of the...- Published at
- by globenewswire.com
positivepositiveXOMA Reports Third Quarter 2023 Financial Results and Highlights Upcoming Events Expected to Drive Shareholder Value
Received $6.6 million in cash receipts during the quarter related to our growing royalty base and certain development milestones One New Drug...